9,180
Total Claims
$1.7M
Drug Cost
955
Beneficiaries
$1,729
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+13%
Cost per patient vs peers
$1,729 vs $1,524 avg
+13%
Brand preference vs peers
15.4% vs 13.7% avg
Brand vs Generic
85% generic
Brand: 1,417 claims · $1.4M
Generic: 7,763 claims · $218K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 559 | $670K |
| Rivaroxaban | 178 | $196K |
| Sacubitril/Valsartan | 124 | $140K |
| Dapagliflozin Propanediol | 146 | $130K |
| Evolocumab | 86 | $77K |
| Dronedarone Hcl | 40 | $61K |
| Alirocumab | 54 | $49K |
| Empagliflozin | 34 | $36K |
| Icosapent Ethyl | 38 | $22K |
| Ezetimibe | 454 | $18K |
| Rosuvastatin Calcium | 911 | $17K |
| Metoprolol Succinate | 796 | $17K |
| Carvedilol Phosphate | 17 | $11K |
| Atorvastatin Calcium | 590 | $9,893 |
| Valsartan | 173 | $9,301 |
Prescribing Profile
67
Unique Drugs
$1.2M
Patient Profile
77
Avg Age
63%
Female
1.28
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data